ThioBridge™: Linking Antibody to Drug with ThioBridge™ Conjugation Technology for Better ADCs

02nd July 2024

Improve your antibody-drug conjugate design and delivery with our ThioBridge™ conjugation technology platform

In the development of antibody-drug conjugates (ADCs), linker technologies are a critical component, particularly those used in first-generation ADC bioconjugation. In our experience these often have limitations that can impact the safety and efficacy of the ADC.

Why choose ThioBridge™?

We developed ThioBridge™ to overcome the limitations associated with traditional linker technologies. Improving the design and delivery of ADCs.

Click here to access the info sheet to learn more about the potential benefits of this newly enhanced platform.

Abzena’s bioconjugation and antibody-drug conjugate expertise

We are a leading, fully integrated bioconjugates & ADCs contract development and manufacturing organization (CDMO). For over 20 years we have refined our expertise in bioconjugation and conjugates to create end-to-end solutions including our ThioBridge™ ADC development platform.

Antibody-drug conjugates